Thomas James Doyle, SVP of Finance and Accounting at Kura Oncology (KURA), sold about $152,000 worth of company shares on the open market in seven transactions over the last year. His most recent sale occurred on January 27, 2026. These sales rank 8,959th among 11,678 insiders, compared to an average of $8.6 million per seller across 6.37 transactions on average. Doyle made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 27, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 695 | $8.46 | 148,774.0000 | 87,645,000 | 0.46% | 0.00% |
| Jan. 27, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 881 | $8.46 | 145,667.0000 | 87,645,000 | 0.60% | 0.00% |
| Jan. 27, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 2226 | $8.46 | 146,548.0000 | 87,645,000 | 1.50% | 0.00% |
| Jan. 27, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 1114 | $8.46 | 149,469.0000 | 87,645,000 | 0.74% | 0.00% |
| Jan. 27, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 2226 | $8.46 | 150,583.0000 | 87,645,000 | 1.46% | 0.00% |
| Jan. 2, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 21250 | $0.00 | 152,809.0000 | 87,645,000 | 16.15% | 0.02% |
| Jan. 2, 2026 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Option to purchase common stock | 42500 | $0.00 | 42,500.0000 | 87,645,000 | 9999.99% | 0.05% |
| Nov. 14, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 4539 | $11.18 | 130,757.0000 | 87,645,000 | 3.35% | 0.01% |
| Nov. 13, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 24967 | $0.00 | 135,296.0000 | 87,645,000 | 22.63% | 0.03% |
| Sept. 29, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 4541 | $8.94 | 110,329.0000 | 86,161,000 | 3.95% | 0.01% |
| Sept. 27, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 24966 | $0.00 | 114,870.0000 | 86,161,000 | 27.77% | 0.03% |
| Jan. 28, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 699 | $7.87 | 89,815.0000 | 86,161,000 | 0.77% | 0.00% |
| Jan. 28, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 887 | $7.87 | 90,514.0000 | 86,161,000 | 0.97% | 0.00% |
| Jan. 28, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 2241 | $7.87 | 91,401.0000 | 86,161,000 | 2.39% | 0.00% |
| Jan. 28, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 1122 | $7.87 | 88,693.0000 | 86,161,000 | 1.25% | 0.00% |
| Jan. 2, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Option to purchase common stock | 42500 | $0.00 | 42,500.0000 | 86,161,000 | 9999.99% | 0.05% |
| Jan. 2, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 21250 | $0.00 | 72,392.0000 | 86,161,000 | 41.55% | 0.02% |
| Jan. 2, 2025 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 21250 | $0.00 | 93,642.0000 | 86,161,000 | 29.35% | 0.02% |
| Jan. 29, 2024 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 594 | $17.80 | 50,317.0000 | 73,229,000 | 1.17% | 0.00% |
| Jan. 29, 2024 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 761 | $17.80 | 49,556.0000 | 73,229,000 | 1.51% | 0.00% |
| Jan. 29, 2024 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 963 | $17.80 | 48,593.0000 | 73,229,000 | 1.94% | 0.00% |
| Jan. 2, 2024 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Option to purchase common stock | 42500 | $0.00 | 42,500.0000 | 73,229,000 | 9999.99% | 0.06% |
| Jan. 2, 2024 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 21250 | $0.00 | 50,911.0000 | 73,229,000 | 71.64% | 0.03% |
| Feb. 16, 2023 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Option to purchase common stock | 63750 | $0.00 | 63,750.0000 | 66,990,000 | 9999.99% | 0.10% |
| Feb. 16, 2023 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | A | Common Stock | 10625 | $0.00 | 27,966.0000 | 66,990,000 | 61.27% | 0.02% |
| Jan. 27, 2023 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 682 | $13.89 | 18,207.0000 | 66,990,000 | 3.61% | 0.00% |
| Jan. 27, 2023 | Kura Oncology, Inc. | $KURA | DOYLE THOMAS JAMES | SVP, Finance & Accounting | S | Common Stock | 866 | $13.89 | 17,341.0000 | 66,990,000 | 4.76% | 0.00% |